AQST vs. PROC, NBTX, EPIX, FBLG, URGN, VNDA, NLTX, CRMD, ORGO, and AKBA
Should you be buying Aquestive Therapeutics stock or one of its competitors? The main competitors of Aquestive Therapeutics include Procaps Group (PROC), Nanobiotix (NBTX), ESSA Pharma (EPIX), FibroBiologics (FBLG), UroGen Pharma (URGN), Vanda Pharmaceuticals (VNDA), Neoleukin Therapeutics (NLTX), CorMedix (CRMD), Organogenesis (ORGO), and Akebia Therapeutics (AKBA). These companies are all part of the "pharmaceutical preparations" industry.
Aquestive Therapeutics (NASDAQ:AQST) and Procaps Group (NASDAQ:PROC) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, dividends, analyst recommendations, earnings, institutional ownership, profitability, community ranking, valuation and risk.
In the previous week, Aquestive Therapeutics had 17 more articles in the media than Procaps Group. MarketBeat recorded 21 mentions for Aquestive Therapeutics and 4 mentions for Procaps Group. Aquestive Therapeutics' average media sentiment score of 0.29 beat Procaps Group's score of 0.22 indicating that Aquestive Therapeutics is being referred to more favorably in the media.
Aquestive Therapeutics has a beta of 2.95, meaning that its stock price is 195% more volatile than the S&P 500. Comparatively, Procaps Group has a beta of 0.16, meaning that its stock price is 84% less volatile than the S&P 500.
Aquestive Therapeutics received 195 more outperform votes than Procaps Group when rated by MarketBeat users. Likewise, 66.67% of users gave Aquestive Therapeutics an outperform vote while only 37.50% of users gave Procaps Group an outperform vote.
Procaps Group has a net margin of 12.61% compared to Aquestive Therapeutics' net margin of -55.85%. Procaps Group's return on equity of 283.06% beat Aquestive Therapeutics' return on equity.
Aquestive Therapeutics presently has a consensus target price of $8.00, suggesting a potential upside of 150.00%. Procaps Group has a consensus target price of $4.50, suggesting a potential upside of 60.71%. Given Aquestive Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Aquestive Therapeutics is more favorable than Procaps Group.
Procaps Group has higher revenue and earnings than Aquestive Therapeutics. Aquestive Therapeutics is trading at a lower price-to-earnings ratio than Procaps Group, indicating that it is currently the more affordable of the two stocks.
32.5% of Aquestive Therapeutics shares are held by institutional investors. 8.4% of Aquestive Therapeutics shares are held by insiders. Comparatively, 19.9% of Procaps Group shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Summary
Aquestive Therapeutics beats Procaps Group on 10 of the 18 factors compared between the two stocks.
Get Aquestive Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for AQST and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AQST and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Aquestive Therapeutics Competitors List
Related Companies and Tools
